152 related articles for article (PubMed ID: 24311440)
1. Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes.
Honda M; Shirasaki T; Shimakami T; Sakai A; Horii R; Arai K; Yamashita T; Sakai Y; Yamashita T; Okada H; Murai K; Nakamura M; Mizukoshi E; Kaneko S
Hepatology; 2014 Mar; 59(3):828-38. PubMed ID: 24311440
[TBL] [Abstract][Full Text] [Related]
2. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.
Honda M; Sakai A; Yamashita T; Nakamoto Y; Mizukoshi E; Sakai Y; Yamashita T; Nakamura M; Shirasaki T; Horimoto K; Tanaka Y; Tokunaga K; Mizokami M; Kaneko S;
Gastroenterology; 2010 Aug; 139(2):499-509. PubMed ID: 20434452
[TBL] [Abstract][Full Text] [Related]
3. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.
Dill MT; Duong FH; Vogt JE; Bibert S; Bochud PY; Terracciano L; Papassotiropoulos A; Roth V; Heim MH
Gastroenterology; 2011 Mar; 140(3):1021-31. PubMed ID: 21111740
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.
Watanabe T; Sugauchi F; Tanaka Y; Matsuura K; Yatsuhashi H; Murakami S; Iijima S; Iio E; Sugiyama M; Shimada T; Kakuni M; Kohara M; Mizokami M
Gut; 2013 Sep; 62(9):1340-6. PubMed ID: 23135762
[TBL] [Abstract][Full Text] [Related]
5. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.
Asahina Y; Tsuchiya K; Muraoka M; Tanaka K; Suzuki Y; Tamaki N; Hoshioka Y; Yasui Y; Katoh T; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nitta S; Sakamoto N; Izumi N
Hepatology; 2012 Jan; 55(1):20-9. PubMed ID: 21898478
[TBL] [Abstract][Full Text] [Related]
6. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.
Naggie S; Osinusi A; Katsounas A; Lempicki R; Herrmann E; Thompson AJ; Clark PJ; Patel K; Muir AJ; McHutchison JG; Schlaak JF; Trippler M; Shivakumar B; Masur H; Polis MA; Kottilil S
Hepatology; 2012 Aug; 56(2):444-54. PubMed ID: 22331604
[TBL] [Abstract][Full Text] [Related]
7. The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.
Younossi ZM; Birerdinc A; Estep M; Stepanova M; Afendy A; Baranova A
J Transl Med; 2012 Feb; 10():25. PubMed ID: 22313623
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.
Kawaoka T; Takahashi S; Takaki S; Hiramatsu A; Waki K; Hiraga N; Miki D; Tsuge M; Imamura M; Kawakami Y; Aikata H; Ochi H; Onoe T; Tashiro H; Ohdan H; Chayama K
J Gastroenterol Hepatol; 2012 Sep; 27(9):1467-72. PubMed ID: 22432893
[TBL] [Abstract][Full Text] [Related]
9. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.
Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
Liver Int; 2011 Oct; 31(9):1359-65. PubMed ID: 21745312
[TBL] [Abstract][Full Text] [Related]
10. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
[TBL] [Abstract][Full Text] [Related]
11. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
Ogurtsov PP; Kukhareva EI
Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730
[TBL] [Abstract][Full Text] [Related]
12. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.
Abe H; Hayes CN; Ochi H; Maekawa T; Tsuge M; Miki D; Mitsui F; Hiraga N; Imamura M; Takahashi S; Kubo M; Nakamura Y; Chayama K
J Hepatol; 2011 Jun; 54(6):1094-101. PubMed ID: 21145800
[TBL] [Abstract][Full Text] [Related]
13. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
Murakawa M; Asahina Y; Kawai-Kitahata F; Nakagawa M; Nitta S; Otani S; Nagata H; Kaneko S; Asano Y; Tsunoda T; Miyoshi M; Itsui Y; Azuma S; Kakinuma S; Tanaka Y; Iijima S; Tsuchiya K; Izumi N; Tohda S; Watanabe M
J Med Virol; 2017 Jul; 89(7):1241-1247. PubMed ID: 28036111
[TBL] [Abstract][Full Text] [Related]
14. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
Umemura T; Ota M; Katsuyama Y; Wada S; Mori H; Maruyama A; Shibata S; Nozawa Y; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Kamijo A; Kobayashi M; Takamatsu M; Yoshizawa K; Kiyosawa K; Tanaka E
Hum Immunol; 2014 Aug; 75(8):822-6. PubMed ID: 24929144
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?
Garcia RF; Moreira S; de Araújo Ramos AL; Ferreira LE; de Mattos AA; Tovo CV; Nader LA; Ramos JA; Rondinelli E; de Jesus Dominici A; Garcia CE; de Souza Leite Pinho M; Brandão-Mello CE; Villela-Nogueira CA; de França PH
World J Gastroenterol; 2013 Nov; 19(42):7399-404. PubMed ID: 24259970
[TBL] [Abstract][Full Text] [Related]
16. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.
Lampertico P; Viganò M; Cheroni C; Facchetti F; Invernizzi F; Valveri V; Soffredini R; Abrignani S; De Francesco R; Colombo M
Hepatology; 2013 Mar; 57(3):890-6. PubMed ID: 22473858
[TBL] [Abstract][Full Text] [Related]
17. Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.
Toyoda H; Kumada T; Hayashi K; Honda T; Katano Y; Goto H; Kawaguchi T; Murakami Y; Matsuda F
J Med Virol; 2011 Sep; 83(9):1559-64. PubMed ID: 21739446
[TBL] [Abstract][Full Text] [Related]
18. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Taniai H; Okada K; Kainuma M; Hayashi J
J Hepatol; 2012 Sep; 57(3):534-40. PubMed ID: 22613000
[TBL] [Abstract][Full Text] [Related]
19. Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype.
Huang CF; Yu ML; Kao JH; Tseng TC; Yeh ML; Huang JF; Dai CY; Lin ZY; Chen SC; Wang LY; Juo SH; Chuang WL; Liu CH
J Clin Virol; 2013 Apr; 56(4):293-8. PubMed ID: 23246359
[TBL] [Abstract][Full Text] [Related]
20. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
